Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
RydaptⓇ - Multi-targeted kinase inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia, pediatrics
Phase 2
20
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia
(AML)
Target Patients
Read-out Milestone(s)
2026
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
108 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation